#United States #cancer therapy #Intensity Therapeutics #Shelton #INT230-6

Intensity Therapeutics Achieves Pinnacle Award Recognition

On April 15, 2026, Intensity Therapeutics, Inc. (NASDAQ: INTS), marked a pivotal moment in its mission to revolutionize cancer treatment by being awarded the prestigious Pinnacle Award for Healthcare Innovation. The company, specializing in developing proprietary cancer therapies, was recognized for its innovative intratumoral injection platform and lead drug candidate, INT230-6.

A New Approach to Cancer Treatment

Intensity's INT230-6 is a novel investigational therapy designed for direct injection into tumors. It combines two well-known anti-cancer agents: cisplatin and vinblastine sulfate, along with a unique molecule known as SHAO that enhances the drug's ability to penetrate and disperse within tumor tissues. This innovative formulation aims to maximize the distribution of potent cytotoxic agents directly to cancer cells, significantly impacting tumor response by improving the body's immune recognition of malignant cells.

“Receiving the Pinnacle Award is a true testament to our relentless dedication to improving cancer care,” said Lewis H. Bender, the Co-Founder and CEO of Intensity Therapeutics. He emphasized that INT230-6 offers a unique approach to provoking cancer cell death, shifting the perception of cancer from an often fatal diagnosis to a manageable chronic disease, even for patients with tumors resistant to conventional immunotherapies.

The Pinnacle Awards

The Pinnacle Awards are an esteemed recognition program that celebrates excellence across various fields, particularly in innovation and impact. Each year, nominees undergo a meticulous selection process involving evaluations by industry experts, media professionals, and consultants. They aim to highlight those who stand out due to exceptional creativity and contributions to their respective sectors. Intensity's victory underscores the innovative spirit driving advancements in cancer treatment.

Clinical Studies Highlight Effectiveness

Intensity Therapeutics has completed multiple clinical studies involving over 200 patients as part of its research on INT230-6. Notable trials include a Phase 1/2 dose escalation study focusing on metastatic cancers, including sarcomas, and a Phase 2 randomized control trial targeting locally advanced breast cancer. Both studies aim to assess the effectiveness of INT230-6 in combination with standard-of-care therapies, focusing on improving patient outcomes and treatment durability. The promising results hint at a substantial shift in how these therapies can be applied, turning treatment-resistant tumors into manageable conditions.

Additionally, the company has embarked on a Phase 3 clinical trial, dubbed the “INVINCIBLE-3 Study,” aimed at evaluating INT230-6 as a stand-alone therapy against soft tissue sarcomas, reinforcing its commitment to innovative and effective cancer treatment.

Future Outlook

The acknowledgment from the Pinnacle Awards serves as motivation for Intensity Therapeutics to continue pursuing groundbreaking research and development in cancer therapies. As the company looks toward future trials and endeavors, the commitment to enhancing life quality for cancer patients remains at the forefront of its mission. These efforts exemplify how focused research and technological innovation in biotechnology can transform existing paradigms in oncology, paving the way for longer-lasting and more effective treatment options.

To learn more about Intensity Therapeutics and its approach to cancer therapeutics, engaging publications, and clinical research updates, visit their official website at www.intensitytherapeutics.com or access their filings with the SEC for comprehensive insights into their operations and future plans.